Lupin enters into prescription dermatology segment in Brazil

23 Aug 2018 Evaluate

Lupin has entered into the prescription dermatology segment in Brazil with the launch of Fillerina and Recrexina under the Lupin High-End Skin Science umbrella. Valued at $28 billion, Brazil is the world's 6th largest pharmaceutical market, driven by growing public health expenditure and increasing household income. The dermatology segment in Brazil, worth $1.5 billion, and growing at 10% (CAGR) is one of the fastest growing segments in the country.

As part of the launch, Lupin has also launched a 360-degree communications campaign, focused on healthcare professionals, pharmacy chains and regional and national medical associations in Brazil.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2190.50 -23.05 (-1.04%)
08-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1761.45
Dr. Reddys Lab 1207.50
Cipla 1460.60
Zydus Lifesciences 907.60
Lupin 2190.50
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×